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1 | INTRODUCTION
Aorto-iliac (Ao-I) disease is quite prevalent and leads to significant limi-
tation in functional status and quality of life. Advances in endovascular
therapy (EVT) techniques in the last 25 years, low risk of peri-
procedural complications and excellent long-term patency have made it
possible to treat most symptomatic patients with Ao-I disease using an
endovascular-first rather than a surgical approach in addition to
guidelines-directed medical therapy. The approach to intra-procedural
assessment of Ao-I lesions has evolved over time to include pressure
gradient measurement and intravascular imaging. In 2017, the Society
for Cardiovascular Angiography and Interventions (SCAI) published an
update to the Appropriate Use Criteria (AUC) for EVT in the Ao-I,
femoral-popliteal (FP), infra-popliteal and renal arterial circulations.1 In
2018, a multi-societal AUC document for EVT was released by the
American College of Cardiology (ACC)/American Heart Association
Abbreviations: ABI, ankle-brachial index; Ao-I, aorto-iliac; AUC, appropriate use criteria; BES,
balloon expandable stent; BMS, bare metal stent; CIA, common iliac artery; CLI, critical limb
ischemia; COR, class of recommendation; CTO, chronic total occlusion; DCB, drug-coated
balloon; DES, drug-eluting stent; DUS, duplex ultrasonography; EIA, external iliac artery; EVT,
endovascular therapy; FP, femoral-popliteal; ISR, in stent restenosis; LOE, level of evidence;
PTA, percutaneous transluminal angioplasty; QoL, quality of life; RCT, randomized clinical
trial; SCAI, Society for Cardiovascular Angiography and Interventions; SES, self-expanding
stent; SFA, superficial femoral artery; TLR, target lesion revascularization; TVR, target vessel
revascularization.
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916 FELDMAN ET AL.
(AHA)/SCAI/Society of Interventional Radiology (SIR)/Society for Vas-
cular Medicine (SVM).2 However, these documents did not address the
selection of specific devices when EVT is indicated. Given the wide
spectrum of available endovascular devices and paucity of comparative
effectiveness data, SCAI developed the first consensus-based guide-
lines document for device selection in femoral-popliteal arterial inter-
ventions in 2018.3 The purpose of this device-focused consensus
document is to provide a comprehensive review of comparative effec-
tiveness data in aorto-iliac arterial interventions, including safety and
efficacy of devices, and to provide clinicians with guidance (class of rec-
ommendation and level of evidence) for device selection, when these
devices are intended as definitive therapy.
2 | METHODOLOGY
This document has been developed according to SCAI Publications
Committee policies for writing group composition, disclosure and
management of relationships with industry (RWI), internal and exter-
nal review, and organizational approval. The writing group has been
organized to ensure diversity of perspectives and demographics,
multi-stakeholder representation, and appropriate balance of RWI.
The author disclosures are included in Table 1. Before appointment,
members of the writing group were asked to disclose all relevant
financial relationships with industry from the 12 months prior to their
nomination. A majority of the writing group disclosed no relevant
financial relationships. Disclosures were periodically reviewed during
document development and updated as appropriate. SCAI policy
requires that writing group members with a current financial interest
be recused from participating in discussions or voting on relevant rec-
ommendations. In December 2019, one group member (MRJ) dis-
closed a new role involving employment by an industry stakeholder;
this member was recused from further participation in document
development (including voting on recommendations and editing docu-
ment) on the effective date of the new role, January 1, 2020. The
work of the writing committee was supported exclusively by SCAI, a
nonprofit medical specialty society, without any commercial support.
Writing group members contributed to this effort on a volunteer basis
and did not receive payment from SCAI.
An evidence review panel developed a protocol and conducted a
systematic review of PubMED, Embase, and CENTRAL datasets using
key search terms Data Data S1) according to established PRISMA
(preferred reporting items for systematic reviews and meta-analyses)
guidelines. Prespecified inclusion criteria for the studies were (1) ran-
domized controlled trials, meta-analyses, registries, nonrandomized
comparative studies, case series and cohort studies; (2) studies com-
paring efficacy and/or safety of endovascular interventions for Ao-I
occlusive disease. The search criteria excluded review articles, edito-
rials, interventions for other arterial beds (ie, femoral-popliteal), arti-
cles solely studying surgical interventions, or those evaluating
interventions for Ao-I aneurysms. Initially, 3,587 articles were identi-
fied. After removal of duplicates and screening of titles and abstracts,
397 full text articles were shortlisted. Further screening was con-
ducted based on specific questionnaire and ultimately 131 articles
were examined in this document (Figure 1) (Data Data S2).
The writing group composed of expert clinicians used a modified
Delphi panel methodology to form and rate recommendations based
on the data extracted during the systematic review. The panel partici-
pated in three rounds of voting, with discussions among the panelists
after the first two anonymized rounds. Each panelist had equal weight
in determining the final rating. Agreement among panelists was
achieved when >80% of the recommendations ratings for the scenar-
ios were concordant (Table 2).
The class (strength) of recommendation (COR) represents the
anticipated magnitude of comparative benefit for a group of devices
(ie, symptom improvement, patency, functional status and/or quality
of life) against the risks and cost of the device use based on the SCAI
(modified ACC/AHA guideline recommendation) classification
(Table 2).3 The Level of Evidence (LOE) represents the quality and
certainty of evidence supporting the effect of the devices on the
TABLE 1 (Continued)





































FELDMAN ET AL. 917
basis of the type, quality, quantity, and consistency of data. The
COR and LOE are determined independently; any COR may be
paired with any LOE.
The draft manuscript was peer reviewed in February 2020 and
the document was revised to address pertinent comments. The writ-
ing group unanimously approved the final version of the document.
The SCAI Publications Committee and Executive Committee endorsed
the document as official society guidance in April 2020. SCAI guide-
lines are primarily intended to help clinicians make decisions about
treatment alternatives. SCAI guidelines do not necessarily follow the
Food and Drug Administration's (FDA) device labeling or the Instruc-
tions for Use (IFUs). Clinicians must consider the clinical and anatomic
presentation, setting, and preferences of individual patients to make
judgements about the optimal approach.
3 | DEFINITIONS AND ASSUMPTIONS
1 The scenarios chosen in this document are largely based upon the
anatomical features of the lesions and presence of hemodynami-
cally significant Ao-I disease rather than clinical presentation and
are not intended to be all-inclusive.
2 Location. The common iliac arteries (CIA) arise from the distal
abdominal aorta and bifurcate to form the external (EIA) and inter-
nal (or hypogastric) iliac arteries. The external iliac artery becomes
the common femoral artery at the inguinal canal while the internal
iliac artery supplies the pelvis, buttocks, genitals, and is a source
of collateral circulation to the intestines. The diameter of the
common iliac arteries ranges from 7 to 12 mm, while the external
iliac artery ranges from 6 to 10 mm. The most recently updated
TASC-IIB document, describes the anatomic characteristics of
Ao-I atherosclerotic disease (Figure 2).4
3 Severity. The significance of Ao-I lesions angiographically determined
by diameter stenosis has been defined as mild (<50%), significant
(≥50%), severe (≥70–99%), and occluded (100% diameter stenosis).
4 Lesion length. Categorized into focal (≤4 cm) and diffuse (>4 cm),
which is consistent with the definitions used for the peripheral
vascular interventions SCAI AUC document.1
5 Calcification. The assessment of lesion calcification is highly subjective
in published trials and registries. The Peripheral Academic Research
Consortium (PARC) document definition was adopted in this docu-
ment, which describes degrees of lesion calcification as (1) focal with
<180 of the vessel wall and less than half the lesion length; (2) mild
with <180 and greater than half the total lesion length; (3) moderate
with ≥180 of the vessel wall and less than half the lesion length; and
(4) severe with ≥180 and greater than half the total lesion length.5
6 In stent restenosis (ISR). ISR is defined as a stenosis or occlusion
within a previously placed stent, regardless of whether the original
stent was bare metal, drug eluting, or covered; caused by inflam-
matory, fibrotic or atherosclerotic process rather than by a throm-
botic occlusion of the stent.
7 For all device scenarios, COR/LOE (Table 2) are provided for
groups or categories of devices and not intended to compare indi-
vidual devices and/or manufacturers.
8 The COR/LOE for a category of the devices were assigned
according to the best comparative data from published trials/
Records identified through database 
searching  
PubMed/MEDLINE, Embase and 
CENTRAL 
(N=3,587)
Additional records identified 
through other sources  
(N=0) 
Records after duplicates removed  
(N=2,343) 
Records screened  
(N=2,343) 





assessed for eligibility  
(N=397) 
Full-text articles excluded, with reasons 
(Review articles/Editorials=195) 
(Surgical interventions=36) 
(Other vascular territories=35) 
(N=266) 
Studies included in 
evidence synthesis  
(N=131) 
F IGURE 1 Selection study
process
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registries, with conventional uncoated balloon PTA frequently
being the comparator. For instance, Class III: No Benefit recom-
mendation implies that there is no benefit relative to the compara-
tor (eg, conventional uncoated balloon PTA), rather than no
benefit at all from the examined category of devices.
9 For device scenarios, this document focuses on the devices when
utilized as the definitive (Table 3), and not necessarily the final
device therapy. BMS may be chosen as the intended definitive
treatment with planned pre-dilation with PTA. Uncoated PTA may
be chosen as the intended definitive treatment, even if it may be
necessary to use “bail-out” stenting to preserve vessel patency.
10 The use of adjunctive devices for lesion preparation is not
addressed in this document.
11 The use of branched and fenestrated stent-grafts (ie, endovascular
aneurysm repair devices) is beyond the scope of this document.
12 The cost of the devices was considered secondary to examining
efficacy and safety data when determining COR/LOE, particularly
for devices with limited comparative clinical data that could justify
their additional cost.
13 Provisional stenting implies PTA with stent placement intended only
for “bail-out” (ie, for significant dissection or >50% residual stenosis).
14 Primary stenting implies the intention to place a stent regardless
of the outcome of any predilation or pretreatment.
4 | CLINICAL OUTCOMES AND
ENDPOINTS, ASSESSING THE EFFICACY OF
REVASCULARIZATION
The primary goal of Ao-I arterial revascularization is relief of intermit-
tent claudication leading to improvement in functional status and qual-
ity of life (QoL), less commonly to relieve the symptoms or signs of
critical limb ischemia (CLI), and occasionally to relieve Ao-I obstruction
to facilitate placement of large bore devices (eg, intra-aortic balloon
pump, percutaneous left ventricular assist device, transcatheter aortic
valve replacement, endovascular aortic repair). Claudication symptoms
often manifest as exertional limb discomfort in the proximal limb
TABLE 2 Applying class of recommendation and level of evidence to device strategies [Color table can be viewed at wileyonlinelibrary.com]
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musculature (ie, buttocks, hips and thighs), suggesting “inflow” arterial
obstruction. The desired outcome is to ameliorate the patient's walking
ability or to reduce symptoms so that they are no longer lifestyle limit-
ing with improvement of arterial perfusion as demonstrated by
improvement in ankle-brachial index (ABI) following treadmill exercise
testing.6
The efficacy of revascularization can be gaged using physiologic and
anatomic parameters. Physiologic efficacy is examined with exercise test-
ing following revascularization, demonstrating relief of claudication using
a standardized protocol and/or by improvement on measures of func-
tional status and QoL (ie, peripheral artery questionnaire). Anatomic
efficacy is most often proven by arterial duplex ultrasonography (DUS)
of the treated segment (including segments proximal and distal to the
treated segment), given its low risk, cost, and accuracy. However, expert
consensus panels are uncertain of the use of serial DUS in asymptomatic
patients following Ao-I revascularization.7
This consensus document recommends adopting the PARC defini-
tions for acute procedural and technical success of EVT, short- and
long-term surrogate endpoints of procedural success (using imaging
and physiologic measures), and functional/clinical outcome defini-
tions.5 In patients with claudication, graded treadmill testing or the
standardized 6-min walk test may be used.8 In this document, when
F IGURE 2 Inter-society consensus for the management of peripheral arterial disease (TASC) classification of aorto-iliac lesions. AAA,
abdominal aortic aneurysm; CFA, common femoral artery; CIA, common iliac artery; EIA, external iliac artery







































































































































































































































































































FELDMAN ET AL. 921
evaluating comparative effectiveness, clinical and physiologic out-
comes are given greater emphasis than surrogate endpoints (eg, DUS-
derived restenosis), which in turn are weighted more heavily than pro-
cedural success endpoints. When available, cost effectiveness studies
were taken into consideration in the recommendations.
5 | DEVICES
5.1 | Uncoated balloons for percutaneous
transluminal angioplasty (PTA)
PTA therapy in Ao-I arteries includes the use of conventional
uncoated balloons. Historically, an “uncoated PTA-first” strategy that
reserves stent placement for “bail-out” was the common initial treat-
ment approach. This strategy can still be utilized in simple lesions
(ie, TASC A or B lesions) given evidence from RCTs. Uncoated PTA
still remains an important adjunctive treatment modality for lesion
preparation in primary stenting.
Outcomes of "uncoated PTA-first” strategy have been com-
pared against supervised exercise and best medical therapy in the
randomized, multicenter MIMIC (Adjuvant benefit of angioplasty in
patients with MIld to Moderate Intermitent Claudication) trial,
showing significant improvements in absolute walking distance
among patients treated with PTA.9 A single-center, prospective
registry of 984 consecutive patients has demonstrated that PTA
was associated with successful outcomes, particularly in those with
claudication due to stenosis of the common iliac artery and good
runoff.10 An analysis of two consecutive periods examined out-
comes of PTA versus PTA plus provisional stenting in 250 patients
that underwent 287 procedures (94% had either common or exter-
nal iliac stenoses).11 Overall, there were no statistically significant
differences in the cumulative primary and secondary patency at
4 years. More recently, a strategy of primary stenting for Ao-I dis-
ease has been compared to “uncoated PTA-first” plus provisional
stenting strategy.12-14 The Dutch iliac stent trial demonstrated that
PTA with provisional stenting (for lesions with a residual gradient
of >10 mm Hg after PTA) had similar clinical outcomes to primary
stenting at 2 years.15 However, this trial excluded patients with
more complex anatomy (lesion length > 10 cm or CTOs > 5 cm). By
employing a provisional stenting strategy in the iliac artery, stent
placement was avoided in 63% of lesions, resulting in a more cost-
effective strategy. After 5-years of follow-up there were no signifi-
cant differences in patency rates, ABI, and quality of life metrics.16
Both strategies appear to provide similar technical success, symp-
tomatic improvement, quality of life and long-term patency for
TASC A and B lesions.17 Based upon comparative data for PTA with
uncoated balloons versus other devices (see further sections), rec-
ommendations for stand-alone uncoated balloon PTA as the
intended definitive therapy in Ao-I disease have been derived
(Table 3 and 4).
5.2 | Specialty balloons for PTA
Specialty balloons have emerged given a potential advantage for treat-
ment of severely calcified and undilatable lesions. In the coronary arteries
the occurrence of balloon slippage, a phenomenon known as “water-
melon seeding,” has been described in ~10% of patients during treatment
of patients with ISR; this phenomenon has also been observed in clinical
practice during Ao-I interventions. Design features include balloons with
microtomes (peripheral cutting balloon [Boston Scientific, Inc.,
Marlborough, MA]) and those with external wire or scaffold to permit
plaque scoring (ie, Angiosculpt scoring balloon [Royal Philips, Amster-
dam, The Netherlands], Chocolate PTA balloon [TriReme Medical, LLC,
Pleasanton, CA]). Despite a lack of RCT data and comparative studies,
particularly in Ao-I vessels, specialty balloon usage has dramatically
increased over time in lower extremity EVT. In the Blue Cross Blue
Shield of Michigan Cardiovascular Consortium PVI Registry of 44,650
prospectively enrolled patients, specialty balloon (namely cutting balloon)
utilization increased from 1.8% in 2006 to 15.1% in 2013 (ptrend < .001).
18
Available outcomes data are observational and focus on immediate tech-
nical success and patency. In the setting of iliac ISR, limited data exist
regarding outcomes after cutting balloon angioplasty as a primary treat-
ment modality as well as after conventional PTA failure.19 The use of
specialty balloons as adjunctive devices for lesion preparation is not
addressed in this document. Consensus recommendations for specialty
balloons utilization as the intended definitive therapy in Ao-I disease
TABLE 4 Recommendations for Percutaneous Transluminal
Angioplasty with Uncoated Balloons as the Intended Definitive
Therapy in the Aorto-Iliac Arterial Interventions [Color table can be
viewed at wileyonlinelibrary.com]
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have been derived below and are based on absence of comparative
effectiveness data and cost (Table 5).
5.3 | Bare metal stents (BMS): Balloon expandable
stents (BES) and self-expanding stents (SES)
A primary stenting strategy for symptomatic Ao-I disease has been
adopted as the preferred clinical practice based on several trials. In
the Dutch iliac stent trial, though there was no difference between
a primary stent strategy versus PTA with provisional stenting with
respect to 5-year patency rates, complex lesions (CTOs > 5 cm and
lesions > 10 cm) were excluded.15 Primary stenting against PTA for
iliac lesions ≤8 cm (mean 5.4 cm) was examined in the STents versus
AnGioplasty (STAG) trial and showed improved technical success
and lower rates of complications with stenting, with similar 2-year
patency rates.14 A meta-analysis of >2,000 patients demonstrated a
43% reduction in 4-year failure with stenting compared to PTA
alone.20
There are two types of BMS available for Ao-I EVT: balloon
expandable (typically composed of stainless steel or cobalt chromium)
stents (BES) and self-expanding stents (SES) composed of nitinol or
stainless steel. BES can be placed more precisely, may be expanded
further post deployment and have greater radial strength.21 These
characteristics may make BES better suited for aorto-ostial common
iliac lesions (ie, Ao-I bifurcation kissing stents), calcific lesions, or
lesions with greater recoil.22 However, BES may create artificial vessel
straightening due to enhanced shear force, perhaps promoting more
neointimal hyperplasia, especially when used in the EIA.23 SES are
available in longer lengths, are more flexible, conform to varying ves-
sel diameters permitting placement within iliac vessels of various
diameters.
Numerous studies have compared BES and SES with varying
results.24-27 A large multicenter retrospective study of 2,147 patients
(one-third BES and two-thirds SES) demonstrated similar primary
patency rates at 5 years between BES (79%) and SES (75%).27 Similar
results were shown in the Japanese Retrospective Analysis of Aorto-Iliac
stenting (REAL-AI) registry.24 In 190 patients who underwent AI bifurca-
tion stenting between 2005 and 2009, the only predictors of restenosis
and need for TLR were female gender and residual diameter stenosis,
stent type (BES or SES) did not predict patency. Similar results have been
reported from the BRAVISSIMO registry, where stent type was not pre-
dictive of 2-year primary patency in 325 patients who underwent Ao-I
stenting.25 Interestingly, only kissing stents configuration and obesity
predicted restenosis in this registry.
The Cordis-supported CRISP-US trial compared two SES by ran-
domizing 203 patients with claudication or rest pain to either the
Shape Memory Allow Recoverable Technology (SMART) nitinol SES
or stainless steel SES (Wallstent) after suboptimal PTA. Acute proce-
dural success was higher in patients assigned to the SMART stent
(98.2 vs. 87.5%, respectively), but incidence of the primary composite
endpoint (30-day death or 9-month restenosis or target vessel revas-
cularization) was similar (6.9 vs. 5.9%), pequivalence = .04.
28
TABLE 5 Recommendations for Percutaneous Transluminal
Angioplasty with Specialty Balloons as the Intended Definitive
Therapy in the Aorto-Iliac Arterial Interventions [Color table can be
viewed at wileyonlinelibrary.com]
TABLE 6 Recommendations for Bare Metal Balloon Expandable
Stents as the Intended Definitive Therapy in the Aorto-Iliac Arterial
Interventions [Color table can be viewed at wileyonlinelibrary.com]
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The only randomized controlled trial to compare BES and SES is
the ICE trial (iliac artery stents for common or external iliac artery
occlusive disease).26 In this trial, 660 patients with CIA or EIA disease
and Rutherford class II–IV symptoms were randomized to either BES
or SES. Pre-dilation was used in 38% of SES and in 26% of BES
implantation and post-dilation was also more common with SES than
BES (93 vs. 22%). SES had lower binary restenosis compared to BES
(6.1 vs. 14.9%, p = .006) and lower rates of TLR (6.9 vs. 3%, p = .041)
at 12 months. In a multivariable analysis, BES remained a significant
predictor of restenosis. A significant interaction was observed with
respect to heavy calcification, where SES performed less well in
heavily calcified lesions than in those with lesser degrees of calcifica-
tion; there was no interaction between lesion type (de novo stenosis,
restenosis, or occlusion), lesion length or lesion location. No differ-
ences were observed for walking impairment and no difference in the
rates of death or amputation were observed between devices.
Regardless of type of stent, the excellent 1-year patency rates of both
groups (93.6% for BES and 97.2% for SES) highlight that endovascular
revascularization with BMS should be considered as first-line for most
Ao-I lesions.
Recommendations for BES and SES in Ao-I ISR lesions are primar-
ily based on limited data from small retrospective studies and expert
consensus. In a retrospective study of 41 lesions (in 24 patients) with
Ao-I ISR treated with an uncoated balloon PTA in all patients, adjunc-
tive stenting was performed in 66% of the lesions.29 The 6- and
12-month primary patency rates were 96% and 82%, respectively.
Consensus recommendations for BES and SES in Ao-I lesions are
listed below (Table 6 and 7).
5.4 | Drug-eluting stents (DES)
DES could theoretically have benefit in the treatment of symptomatic
Ao-I occlusive disease; however, currently available devices have not
been systematically studied in iliac artery occlusive disease. Limited
sizes of DES are available for iliac arteries, with the largest available
DES in US to date being 8.0 mm in diameter. DES have shown
improved patency and reduction in TLR compared to uncoated bal-
loon angioplasty or BMS implantation in FP lesions.30,31 One small
study examining Eluvia DES implantation in the external iliac and FP
arteries reported 6-month primary patency and freedom from TLR of
92%.32 Given the findings of a recent meta-analysis33 and concerns
about late mortality with paclitaxel-eluting technologies, consideration
should be given regarding the risks and benefits of DES (or DCB) prior
to their use in Ao-I arteries.34 Potential risks of late mortality and ben-
efits of reduced restenosis should be discussed with patients.
TABLE 7 Recommendations for Bare Metal Self-Expanding
Stents as the Intended Definitive Therapy in the Aorto-Iliac Arterial
Interventions [Color table can be viewed at wileyonlinelibrary.com]
TABLE 8 Recommendations for Drug-Eluting Stents as the
Intended Definitive Therapy in the Aorto-Iliac Arterial Interventions
[Color table can be viewed at wileyonlinelibrary.com]
924 FELDMAN ET AL.
Furthermore, clinicians should perform diligent monitoring of patients
who have been treated with DES or DCB devices (Table 8).
5.5 | Drug-coated balloons (DCB)
Similar to DES, there are no randomized or prospective studies that
have evaluated the role of DCB for the treatment of Ao-I disease. Theo-
retically, these devices may have a role for Ao-I in-stent restenosis or
occlusion. However, given the lack of safety and efficacy data
addressing the use of DCBs in Ao-I segment, and extensive long-term
data in support of BMS or covered stents, DCB use should be very
limited at this time. Furthermore, limited sizes of DCBs are available
for iliac arteries, with the largest available DCB in US to date being
7.0 mm in diameter. If DCB are to be used, FDA recommendations
should be taken into consideration (as discussed in Section 4.3.1)34
(Table 9).
5.6 | Covered (endovascular grafts) stents: Balloon
expandable and self-expanding
Covered stents comprise a metallic scaffold lined with poly-
tetrafluoroethylene (PTFE) or Dacron material. These stents are used
during percutaneous Ao-I artery revascularization either as an endo-
vascular prosthesis for treatment of atherosclerotic disease or for bail-
out treatment of arterial perforation, exclusion of thrombus, and
exclusion of aneurysms. By excluding underlying plaque from the
lumen, covered stents limit encroachment of the arterial lumen by
neointimal hyperplasia and thereby potentially reduce restenosis com-
pared with uncovered BMS. Covered stents are commonly used in the
treatment of calcified or ectatic common iliac vessels, where they may
provide a safety margin due to risk of arterial rupture. There are two
types of covered stents for Ao-I interventions: balloon expandable
and self-expanding. Similar to uncovered BES and SES, covered BES
provide greater radial strength and allow precise stent placement,
whereas covered SES offer greater flexibility. Covered stents can
migrate, thrombose, develop edge restenosis, result in loss of side bra-
nches (ie, internal iliac artery), and may require longer treatment with
antiplatelet agents. In contemporary US clinical practice four types of
covered stents are available: the iCAST™ (Atrium Medical Corp, Hud-
son, NH), VBX Stent Graft (W.L. Gore & Associates, Inc, Flagstaff, AZ),
Viabahn® endoprosthesis (W.L. Gore & Associates, Inc, Flagstaff, AZ)
and Lifestream stent (Bard, Tempe, AZ).
The iCAST™ is a balloon-expandable stent with an inner and an
outer layer of PTFE material. It is FDA approved for treatment of tra-
cheobronchial structures, however, it is frequently used off-label during
endovascular Ao-I artery revascularization. This off-label use is supported
TABLE 10 Recommendations for Covered Balloon Expandable
Stents as the Intended Definitive Therapy in the Aorto-Iliac Arterial
Interventions [Color table can be viewed at wileyonlinelibrary.com]
TABLE 9 Recommendations for Drug Coated Balloons as the
Intended Definitive Therapy in the Aorto-Iliac Arterial Interventions
[Color table can be viewed at wileyonlinelibrary.com]
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by the Covered Versus Balloon-Expandable Stent Trial (COBEST); the
only published multicenter randomized clinical trial utilizing covered
stents.35 The trial included 168 TASC B to D lesions in 125 participants
randomized to either iCAST stent versus uncovered balloon-expandable
BMS. Lesions treated with a covered stent were significantly more likely
to remain free from binary restenosis at 18 months (HR: 0.35, p < .02).
Post hoc subgroup analysis demonstrated a significantly lower binary
restenosis in TASC C and D lesions with covered stents versus BMS
(HR: 0.14, 95% CI 0.04–0.44), however, there was no difference for
TASC B lesions (HR: 0.75, 95% CI 0.24–2.39). Most re-interventions
occurred between 12–18 months, with fewer in the covered stent
group. The improved patency with the iCAST stent was sustained at
5 years.36 Observational evidence comparing the iCAST stent to a group
of balloon-expandable BMS found significantly better primary, assisted
and secondary patency with BMS; the TASC classification did not predict
reintervention.37 Dual antiplatelet therapy was predictive of long-term
patency on multivariate analysis. The use of multiple iCAST stents has
also been described for treatment of complex Ao-I bifurcations using a
technique termed CERAB (covered endovascular reconstruction of the
aortic bifurcation).38
The VBX Stent Graft, balloon expandable covered stent, was
FDA approved in 2017 for the treatment of de novo or restenotic
Ao-I lesions, including Ao-I bifurcation. This stent consists of
discrete stainless steel rings that are fully encapsulated in fluo-
ropolymer and coated with heparin. In the first-in-man study
30 symptomatic patients were enrolled in a single arm prospective
single center study.39 The primary safety endpoint, a composite of
device or procedure-related death, MI, or amputation in the treated
leg within 30 days of the procedure was 0%. Primary patency, free-
dom from TLR, and freedom from TVR were 100% at 1 and
6 months and 96.6% at 12 months. The VBX Flex multicenter single
arm study results (134 patients, 213 iliac lesions) affirm 100% tech-
nical success and 97% 9-month patency with this stent in “real-
world” iliac artery lesions involving tortuosity, severe calcification,
total occlusion, and direct stenting and/or kissing stent treatment
at the Ao-I bifurcation.40 In TASC C and D lesions, that comprised
over a third of cases, 9-month patency was 95%.
The Viabahn endoprosthesis is a self-expanding stent with nitinol
support extending along its entire length and an expanded PTFE lining.
It is highly flexible and FDA approved for the treatment of patients
with symptomatic iliac artery lesions. There are no randomized trials
comparing the efficacy and safety of the Viabahn endoprosthesis to
other covered or balloon-expandable stents in the iliac artery. A pro-
spective study of 61 iliac arteries reported primary patency rate of
98% at 6 months and 91% at 12 months.41 Two cases of embolization
of the endoprosthesis to distal arteries were observed in the study.
The Viabahn stents in EIA have been used in combination with iCAST
or other balloon expandable stents in the aorta and common iliac
TABLE 11 Recommendations for Covered Self-Expanding Stents
as the Intended Definitive Therapy in the Aorto-Iliac Arterial
Interventions [Color table can be viewed at wileyonlinelibrary.com]
TABLE 12 Recommendations for Atherectomy as the Intended
Definitive Therapy in the Aorto-Iliac Arterial Interventions [Color
table can be viewed at wileyonlinelibrary.com]
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segments to treat complex Ao-I occlusive disease involving EIAs.
A recent retrospective study of Ao-I cases observed similar mid-term
patency with the Viabahn and balloon expandable BMS.42 The
Viabahn stent performed better in TASC D lesions, occlusive lesions
with a total lesion length > 6 cm, occlusion length > 3.5 cm and in
heavily calcified lesions.
The Lifestream balloon expandable covered stent is the most
recently US approved iliac stent. The results of a multicenter single
arm trial of 155 patients, balloon expandable vascular covered stent in
the treatment of iliac artery occlusive disease (BOLSTER), evaluated
the performance of this stainless steel stent encapsulated between
two stretched PTFE layers.43 At 9 months, primary patency was
89.1% and freedom from TLR was 96.1% by Kaplan–Meier estimate.
These results were accompanied by improvements in Rutherford cate-
gory from baseline and QoL scores.
Overall, there is limited high-quality comparative evidence for
the routine use of covered stents in the Ao-I artery distribution.
A meta-analysis of covered stents in Ao-I and FP arteries concluded
that primary patency was improved with the covered stents in the
FP distribution, but not Ao-I.44 Currently, covered stents are selec-
tively used to treat iliac artery perforations and excluding thrombus
or arterial aneurysms. However, there are data to support the clini-
cal efficacy of covered stents, especially balloon expandable, in
treatment of TASC C and D Ao-I artery lesions. Consensus recom-
mendations for covered BES and SES in Ao-I lesions are listed
below (Table 10 and 11).
5.7 | Atherectomy
While use of many devices including directional atherectomy and laser
atherectomy has been reported in the treatment of Ao-I disease, rota-
tional atherectomy is the only treatment modality with available data.
The CONFIRM I, II, and III registries prospectively enrolled 3,135
patients with PAD in different segments and 4,766 lesions at over
200 U.S. centers. Demographic data, lesion characteristics, and pro-
cedure outcomes for the CONFIRM patients with at least one iliac
artery lesion treated with orbital atherectomy (62 patients;
68 lesions) were compared to patients with at least one SFA lesion
treated with orbital atherectomy (1,570 patients; 1,809 lesions).45
The procedural complication rates, defined as the composite of flow
limiting dissection, perforation, slow flow, vessel closure, spasm,
embolism, or thrombosis, were compared in iliac lesions versus SFA
lesions. The iliac group had one reported perforation and one
reported vessel closure; the rates of slow flow, spasm, embolism,
thrombus, and flow limiting dissection were 0%. The overall proce-
dural complication rate was significantly lower in the iliac group (2.9
vs. 11.2%, p = .03). Potential risks of different atherectomy devices
in Ao-I location include distal embolization, dissection and perfora-
tion; in Ao-I ISR lesions atherectomy devices can lead to stent strut
damage and excision of stent fragments. Further data regarding
adjunctive use of atherectomy devices in Ao-I locations are needed
(Table 12).
5.8 | Adjunctive therapies
In addition to atherectomy, alternate approaches for lesion prepara-
tion of the Ao-I arteries have been investigated. Notably, cryoplasty
and intravascular lithotripsy have been FDA approved for angioplasty
and treatment of calcified arteries in 2002 and 2018, respectively. Ini-
tial experience with cryoplasty in the FP arteries suggested modest
success with respect to early patency, however, longer term follow-up
demonstrated no benefit compared to conventional PTA.46-49 Subse-
quent studies confirmed this lack of benefit, and thus cryoplasty has
been largely abandoned for adjunctive treatment in the Ao-I and FP
segments.
Intravascular lithotripsy (Shockwave Medical, Santa Clara, CA)
functions by incorporating lithotripsy emitters within an angio-
plasty balloon, such that sonic pressure waves drive through sur-
rounding tissue selectively fracturing vascular calcium within the
vessel wall, thus purportedly altering vessel compliance and permit-
ting vessel dilatation at relatively low pressures. Early studies with
intravascular lithotripsy have demonstrated feasibility for the man-
agement of severely calcified arterial stenoses in coronary and
peripheral arteries.50-54 With respect to Ao-I artery revasculariza-
tion, several case reports have demonstrated potential value in the
management of Ao-I occlusive disease,55 particularly when large
bore catheter access is required,56 however, RCTs for an Ao-I appli-
cation are yet to be performed.
6 | FUTURE RESEARCH DIRECTIONS
Ao-I endovascular intervention has evolved rapidly over the past
several decades. Early sources of complications (ie, perforations)
have been addressed with novel lesion preparation approaches and
covered stent grafts. However, there remain numerous challenges
to the management of this lesion subset. The development of inte-
grated Ao-I prostheses for occlusive disease continues to expand
our options for treating these complex patients. Moreover, alter-
nate, “small bore” approaches to treating Ao-I occlusive disease
continue to evolve. In addition, while drug-eluting technologies
have emerged as clearly superior in terms of preventing restenosis
in other vascular territories, the development of DES or DCB for Ao-I
indications remains an unmet need. Large RCTs and post-market regis-
tries for both coronary and FP applications of intravascular lithotripsy
are currently ongoing. Long-term data on lithotripsy in Ao-I lesions are
needed. Comparative effectiveness trials are needed to provide the only
scientifically valid approach to identify the relative value of these
techniques.
7 | CONCLUSION
The SCAI writing committee conducted a comprehensive, systematic
review and analysis of the scientific evidence and developed concise,
focused, unbiased device-specific recommendations for Ao-I EVT.
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These recommendations are designed to assist clinicians with relevant
anatomical scenarios and to guide device selection in Ao-I location
based on strength and quality of evidence for comparative effective-
ness, durability and expert opinion.
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